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Signaling by NO/cGMP/cGMP-dependent kinase I (cGKI)
is important for a variety of physiological functions com-
prising relaxation of smooth muscle and inhibition of
platelet aggregation. An important pathway of this signal-
ing cascade includes the inositol 1,4,5-trisphosphate
receptor I (IP3RI) associated protein cGMP kinase sub-
strate (IRAG). This protein interacts in a trimeric macro-
complex with cGKIβ and the IP3RI. To get insight into the
physiological function of IRAG two different mice strains
were generated by targeted deletion: (1) IRAGΔ12/Δ12 with
an exon 12 deletion disrupting the IRAG/IP3RI interac-
tion. (2) IRAG-/- with an exon 3 deletion generating an
IRAG knockout mutant.
Analysis of IRAGΔ12/Δ12 platelet aggregation in vitro using
collagen and thrombin as agonists and Fura2 calcium
measurements revealed that IP3RI/IRAG interaction is
essential for NO/cGMP signaling mediating inhibition of
platelet aggregation. Furthermore, it was shown that
IP3RI/IRAG interaction is essential for the NO-dependent
prevention of thrombus formation.
Relaxation of hormone-contracted aortic and longitudi-
nal colonic smooth muscle by cGMP was abolished in
IRAGΔ12/Δ12 mice and IRAG knockout mice indicating an
essential role of IRAG for NO/cGMP-dependent smooth
muscle relaxation. The vascular function of IRAG was
underlined by a lack of NO-dependent blood pressure
reduction in IRAGΔ12/Δ12 mice. These studies suggest that
cGKI/IRAG/IP3RI is an essential signaling pathway modu-
lating cardiovascular functions.
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